Tweet
<img alt="" height="1" width="1" />
Analysts Applaud Gilead's Hepatitis C Drug
Barron's (blog)
Gilead Sciences (GILD) has certainly had its share of pain recently, hurt by the selloff in momentum stocks, particularly biotech, and concerns about competition. However, the shares were trading up on Monday, helped by several positive commentaries about ...
and more »
More...